![]() |
![]() |
Product | Quantum (Rs. Cr) | Long Term Rating | Short Term Rating |
Bank Loan Ratings | 72.00 | ACUITE C | Downgraded | Issuer not co-operating* | - |
Bank Loan Ratings | 8.00 | - | ACUITE A4 | Reaffirmed | Issuer not co-operating* |
Total Outstanding | 80.00 | - | - |
Total Withdrawn | 0.00 | - | - |
* The issuer did not co-operate; based on best available information. |
Rating Rationale |
Acuité has downgraded the long-term rating to ‘ACUITE C’ (read as ACUITE C) from ‘ACUITE B’ (read as ACUITE B) on the Rs. 72.00 Crore bank facilities and reaffirmed short term rating at 'ACUITE A4' (read as ACUITE A four) on the Rs. 8.00 Crore bank facilities of Amogen Pharma Private Limited (APPL). The rating continues to be flagged as “Issuer Not Co-operating”and is based on the best available information. |
About the Company |
Amogen Pharma Private Limited, incorporated in 2020. The main objective of the Company is to undertake the business of Bio Pharma Active Pharmaceutical Ingredients manufacturing. At Present, APPL is constructing the factory as per its proposed 1200 KPA (Kgs per annum) Active Pharmaceutical Ingredients (API) manufacturing plant at Karkapatla village, Siddipet district, Telangana. Company has received all the necessary approvals for construction of the plant. The Directors of the company are Mr. Poosapati Venkata Surya Narasimha Raju, Ms. Thakasi Devi Kalyan Kumar and Mr. Akhilesh Raju Pusapati.The Registered office of the company is in Hyderabad. |
Unsupported Rating |
Not Applicable |
Non-cooperation by the issuer/borrower: |
Acuité has been requesting for data, information and undertakings from the rated entity for conducting surveillance & review of the rating. However, the issuer/borrower failed to submit such information before the due date. Acuité believes that information risk is a critical component in such ratings, and noncooperation by the issuer along with unwillingness to provide information could be a sign of potential deterioration in its overall credit quality. This rating is, therefore, being flagged as “Issuer not-cooperating”, in line with prevailing SEBI regulations and Acuité’s policies. |
Limitation regarding information availability |
Rating Sensitivity |
"No information provided by the issuer / available for Acuite to comment upon." |
Liquidity Position |
"No information provided by the issuer / available for Acuite to comment upon." |
Outlook: Not Applicable |
|
Other Factors affecting Rating |
None |
Particulars | Unit | FY 24 (Actual) | FY 23 (Actual) |
Operating Income | Rs. Cr. | 0.00 | 0.00 |
PAT | Rs. Cr. | (0.32) | (0.29) |
PAT Margin | (%) | 0.00 | 0.00 |
Total Debt/Tangible Net Worth | Times | 2.04 | 0.20 |
PBDIT/Interest | Times | 0.00 | 0.00 |
Status of non-cooperation with previous CRA |
Not Applicable |
Any other information |
None |
Applicable Criteria |
• Manufacturing Entities: https://www.acuite.in/view-rating-criteria-59.htm • Default Recognition: https://www.acuite.in/view-rating-criteria-52.htm • Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm |
Note on complexity levels of the rated instrument |
|
|
|
|||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
* The issuer did not co-operate; based on best available information. |
Contacts |
About Acuité Ratings & Research |
© Acuité Ratings & Research Limited. All Rights Reserved. | www.acuite.in |